Insider · CIK 0001950551
Erick Gamelin
officer
Files at ACRV (Acrivon Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -403 | $1.14 | $459 | 16,089 | May 16, 2025 |
| Mar 1, 2025 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +78,078 | $0.00 | $0 | 78,078 | Mar 4, 2025 |
| Feb 14, 2025 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -469 | $5.42 | $2,542 | 16,492 | Feb 19, 2025 |
| Mar 1, 2024 | ACRV Acrivon Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,045 | $0.00 | $0 | 45,045 | Nov 27, 2024 |
| Nov 14, 2024 | ACRV Acrivon Therapeutics, Inc. | FTax withholding Common Stock | -402 | $7.92 | $3,184 | 16,961 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.